downgrad market perform base new
stock perform well recent trade approach
all-tim high juli occur follow launch hiseq
broadli one innov compani coverag list stellar
manag team moreov continu believ market evolv linearli
demonstr sequenc market highli elast addit channel
check sinc initi launch point fact novaseq real new product
cycl separ result recent survey conduct conjunct genomeweb
publish note titl conclus survey conduct collabor
genom web show on-going invest sequenc instrument
consum thu reluct re-consid rate
ultim howev product cycl compani thu seen wave new
product adopt illustr exhibit outlin mani time
past stock performance/valu driven acceleration/
deceler instrument growth go back first launch hiseq
share price depreci typic preced declin instrument revenu
quarter two may look simpli instrument comparison
becom much difficult second quarter prior launch
typic seen bolu adopt first four six quarter exhibit
estim revenu growth crept histor
manag provid preliminari fourth quarter result guidanc
morgan confer expect manag gener guid line street see
upsid number thu may quarter two earli rate chang
see upsid mostli fourth quarter first quarter particularli
launch chip novaseq fourth quarter thu may quarter two
earli rate chang particularli given easi comparison first quarter
scenario analysi last publish note titl understand genom
symposium highlight futur genom updat illumina scenario analysi suggest
potenti much revenu growth bullish case exhibit
base forward price-to-earnings multipl preced
new product cycl ramp-up analysi suggest stock price illustr
exhibit upsid current level stock current trade time
current adjust ep ultim believ applic becom
import growth sequenc move consist recur clinic
consumer-bas approach meantim believ investor may better
serv wait deceler novaseq product cycl entri point thu
downgrad stock market perform
provid proprietari life scienc tool microarray support genet analysi custom
includ genom research center academ institut pharmaceut biotech compani clinic lab
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
return equiti ttm
estim quarterli instrument placement variou illumina product launch
bullish case repres larger quicker product cycl
impli price base price-to-earnings target
up/downsid stock price
